<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357614</url>
  </required_header>
  <id_info>
    <org_study_id>IT001-302</org_study_id>
    <nct_id>NCT03357614</nct_id>
  </id_info>
  <brief_title>Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults</brief_title>
  <official_title>Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability &amp; Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iterum Therapeutics, International Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iterum Therapeutics, International Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, phase 3, randomized, multicenter, double-blind, double-dummy study to&#xD;
      compare the efficacy and safety of sulopenem followed by sulopenem-etzadroxil/probenecid&#xD;
      versus ertapenem followed by ciprofloxacin for the treatment of complicated urinary tract&#xD;
      infections (cUTI) in adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">December 14, 2019</completion_date>
  <primary_completion_date type="Actual">December 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Overall Success</measure>
    <time_frame>Day 21 +/- 1 day</time_frame>
    <description>Clinical success is defined as complete resolution of cUTI symptoms present at study entry and no new cUTI symptoms; microbiologic success is defined as eradication of the bacterial pathogen found at study entry (reduced to &lt;1000 CFU/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiologic Success</measure>
    <time_frame>Day 21 +/- 1 day</time_frame>
    <description>Microbiologic success is defined as demonstrating &lt;1000 CFU/mL of the baseline urpathogen by quantitative urine culture</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1395</enrollment>
  <condition>Complicated Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Sulopenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulopenem</intervention_name>
    <description>Antibiotic therapy for complicated UTI</description>
    <arm_group_label>Sulopenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulopenem-Etzadroxil/Probenecid</intervention_name>
    <description>Antibiotic therapy for complicated UTI</description>
    <arm_group_label>Sulopenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Antibiotic therapy for complicated UTI</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Invanz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Antibiotic therapy for complicated UTI</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-clavulanate</intervention_name>
    <description>Antibiotic therapy for complicated UTI</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Augmentin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults ≥18 years of age with more than 24 hours of urinary symptoms attributable to a&#xD;
             UTI&#xD;
&#xD;
          2. Able to provide informed consent&#xD;
&#xD;
          3. Clinically documented pyelonephritis or complicated urinary tract infection:&#xD;
&#xD;
               1. Pyelonephritis with normal anatomy&#xD;
&#xD;
               2. Complicated UTI as defined by one or more of the following factors:&#xD;
&#xD;
             i. The presence of an indwelling catheter ii. &gt;100 mL of residual urine after voiding&#xD;
             iii. Neurogenic bladder iv. Obstructive uropathy due to nephrolithiasis, tumor or&#xD;
             fibrosis v. Azotemia due to intrinsic renal disease vi. Urinary retention in men&#xD;
             possibly due to benign prostatic hypertrophy vii. Surgically modified or abnormal&#xD;
             urinary tract anatomy&#xD;
&#xD;
          4. At least two of the following signs or symptoms:&#xD;
&#xD;
               1. Rigors, chills or fever/hypothermia&#xD;
&#xD;
               2. Flank pain or pelvic pain&#xD;
&#xD;
               3. Nausea or vomiting&#xD;
&#xD;
               4. Dysuria, urinary frequency or urinary urgency&#xD;
&#xD;
               5. Costovertebral angle tenderness on physical examination&#xD;
&#xD;
          5. A mid-stream urine specimen with:&#xD;
&#xD;
               1. a dipstick analysis positive for nitrite AND&#xD;
&#xD;
               2. evidence of pyuria as defined by either: i. a dipstick analysis positive for&#xD;
                  leukocyte esterase AND/OR ii. at least 10 white blood cells per cubic millimeter&#xD;
                  on microscopic analysis of unspun urine AND/OR iii. White blood cell count ≥10&#xD;
                  cells/high-powered field in urine sediment&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Receipt of effective antibacterial drug therapy for complicated urinary tract&#xD;
             infection (cUTI) for a continuous duration of more than 24 hours during the previous&#xD;
             72 hours. Patients who have objective documentation of clinical progression of cUTI&#xD;
             while on antibacterial drug therapy, or patients who received antibacterial drugs for&#xD;
             surgical prophylaxis and then develop cUTI, may be appropriate for enrollment.&#xD;
&#xD;
          2. Subjects with an organism isolated from the urine within the last year known to be&#xD;
             resistant to ertapenem&#xD;
&#xD;
          3. Severe structural or functional urinary tract abnormality responsible for an&#xD;
             intractable infection which in the opinion of the investigator would require &gt; 10 days&#xD;
             of therapy or post-treatment prophylaxis (eg. patients with chronic vesiculo-ureteral&#xD;
             reflux).&#xD;
&#xD;
          4. Uncomplicated UTI&#xD;
&#xD;
          5. Patients with paraplegia/quadriplegia&#xD;
&#xD;
          6. Hypotension with systolic blood pressure &lt; 90 mm Hg&#xD;
&#xD;
          7. Complicated UTI associated with complete obstruction, emphysematous pyelonephritis,&#xD;
             known or suspected renal or perinephric abscess or expected to require surgical&#xD;
             intervention (not placement of catheters) to achieve cure&#xD;
&#xD;
          8. Patients with a known history of myasthenia gravis&#xD;
&#xD;
          9. Patients who require concomitant administration of tizanidine or valproic acid&#xD;
&#xD;
         10. Patients with a history of allergy to carbapenems or quinolones or&#xD;
             amoxicillin-clavulanate or other beta-lactams, or hypersensitivity to probenecid&#xD;
&#xD;
         11. Renal transplantation&#xD;
&#xD;
         12. Patients requiring dialysis&#xD;
&#xD;
         13. Acute or chronic prostatitis&#xD;
&#xD;
         14. High risk for cUTI caused by Pseudomonas sp. (eg,. history of prior UTI due to&#xD;
             Pseudomonas species, recent steroid use, others)&#xD;
&#xD;
         15. Chronic indwelling catheters or stents&#xD;
&#xD;
         16. Ileal loops or vesico-urethral reflux&#xD;
&#xD;
         17. Recent trauma to the pelvis or urinary tract within the prior 30 days&#xD;
&#xD;
         18. History of seizures&#xD;
&#xD;
         19. Patients with a history of blood dyscrasias&#xD;
&#xD;
         20. Patients with a history of uric acid kidney stones&#xD;
&#xD;
         21. Patients with acute gouty attack&#xD;
&#xD;
         22. Patients on chronic methotrexate therapy&#xD;
&#xD;
         23. Females of child-bearing potential who are unable to take adequate contraceptive&#xD;
             precautions, have a positive pregnancy test result within 24 hours of study entry, are&#xD;
             otherwise known to be pregnant, or are currently breastfeeding an infant.&#xD;
&#xD;
         24. Male subjects must agree to use of an effective barrier method of contraception during&#xD;
             the study and for 14 days post treatment&#xD;
&#xD;
         25. Patients known to have a history of liver or kidney disease or neutropenia as defined&#xD;
             by the following baseline laboratory criteria:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) &gt; 3 X Upper&#xD;
                  Limit of Normal&#xD;
&#xD;
               -  Total bilirubin &gt; 2 X Upper Limit of Normal&#xD;
&#xD;
               -  Neutropenia (&lt;1000 cells/mm3)&#xD;
&#xD;
         26. Patients participating in any other clinical study that involved the administration of&#xD;
             an investigational medication&#xD;
&#xD;
         27. Patient immunocompromised&#xD;
&#xD;
         28. Patients unlikely to comply with the protocol&#xD;
&#xD;
         29. Patients considered unlikely to survive the 4-week study period or has a rapidly&#xD;
             progressive or terminal illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>90623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Kohtla-Järve</city>
        <zip>31025</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Võru</city>
        <zip>65526</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tbilisi</city>
        <zip>00144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tbilisi</city>
        <zip>00159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tbilisi</city>
        <zip>00160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Budapest</city>
        <zip>01204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Szentes</city>
        <zip>06600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tatabánya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Liepāja</city>
        <zip>LV3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Riga</city>
        <zip>LV1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Riga</city>
        <zip>LV1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Valmiera</city>
        <zip>LV4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <results_first_submitted>November 5, 2020</results_first_submitted>
  <results_first_submitted_qc>December 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 29, 2020</results_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03357614/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03357614/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sulopenem</title>
          <description>Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Sulopenem: Antibiotic therapy for complicated UTI&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic therapy for complicated UTI</description>
        </group>
        <group group_id="P2">
          <title>Ertapenem</title>
          <description>Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Ertapenem: Antibiotic therapy for complicated UTI&#xD;
Ciprofloxacin: Antibiotic therapy for complicated UTI&#xD;
Amoxicillin-clavulanate: Antibiotic therapy for complicated UTI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="697"/>
                <participants group_id="P2" count="698"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="672"/>
                <participants group_id="P2" count="670"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulopenem</title>
          <description>Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Sulopenem: Antibiotic therapy for complicated UTI&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic therapy for complicated UTI</description>
        </group>
        <group group_id="B2">
          <title>Ertapenem</title>
          <description>Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Ertapenem: Antibiotic therapy for complicated UTI&#xD;
Ciprofloxacin: Antibiotic therapy for complicated UTI&#xD;
Amoxicillin-clavulanate: Antibiotic therapy for complicated UTI</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="697"/>
            <count group_id="B2" value="698"/>
            <count group_id="B3" value="1395"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="18.2"/>
                    <measurement group_id="B2" value="59.3" spread="18.2"/>
                    <measurement group_id="B3" value="58.5" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="389"/>
                    <measurement group_id="B2" value="380"/>
                    <measurement group_id="B3" value="769"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="318"/>
                    <measurement group_id="B3" value="626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="672"/>
                    <measurement group_id="B2" value="675"/>
                    <measurement group_id="B3" value="1347"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Overall Success</title>
        <description>Clinical success is defined as complete resolution of cUTI symptoms present at study entry and no new cUTI symptoms; microbiologic success is defined as eradication of the bacterial pathogen found at study entry (reduced to &lt;1000 CFU/mL)</description>
        <time_frame>Day 21 +/- 1 day</time_frame>
        <population>Analysis population is the microbiologic modified intent-to-treat population (all modified intent-to-treat patients with a positive study entry urine culture within 48 hours prior to first dose, defined as &gt;100,000 CFU/mL of a uropathogen and no more than 2 species of a uropathogen &gt;100,000 CFU/mL; if 1 of the uropathogens was also isolated from baseline blood culture, however, the patient was included in this population regardless of the baseline urine culture result).</population>
        <group_list>
          <group group_id="O1">
            <title>Sulopenem</title>
            <description>Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Sulopenem: Antibiotic therapy for complicated UTI&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic therapy for complicated UTI</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Ertapenem: Antibiotic therapy for complicated UTI&#xD;
Ciprofloxacin: Antibiotic therapy for complicated UTI&#xD;
Amoxicillin-clavulanate: Antibiotic therapy for complicated UTI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Success</title>
          <description>Clinical success is defined as complete resolution of cUTI symptoms present at study entry and no new cUTI symptoms; microbiologic success is defined as eradication of the bacterial pathogen found at study entry (reduced to &lt;1000 CFU/mL)</description>
          <population>Analysis population is the microbiologic modified intent-to-treat population (all modified intent-to-treat patients with a positive study entry urine culture within 48 hours prior to first dose, defined as &gt;100,000 CFU/mL of a uropathogen and no more than 2 species of a uropathogen &gt;100,000 CFU/mL; if 1 of the uropathogens was also isolated from baseline blood culture, however, the patient was included in this population regardless of the baseline urine culture result).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="444"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301"/>
                    <measurement group_id="O2" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiologic Success</title>
        <description>Microbiologic success is defined as demonstrating &lt;1000 CFU/mL of the baseline urpathogen by quantitative urine culture</description>
        <time_frame>Day 21 +/- 1 day</time_frame>
        <population>Analysis population is the microbiologic modified intent-to-treat population (all modified intent-to-treat patients with a positive study entry urine culture within 48 hours prior to first dose, defined as &gt;100,000 CFU/mL of a uropathogen and no more than 2 species of a uropathogen &gt;100,000 CFU/mL; if 1 of the uropathogens was also isolated from baseline blood culture, however, the patient was included in this population regardless of the baseline urine culture result).</population>
        <group_list>
          <group group_id="O1">
            <title>Sulopenem</title>
            <description>Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Sulopenem: Antibiotic therapy for complicated UTI&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic therapy for complicated UTI</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Ertapenem: Antibiotic therapy for complicated UTI&#xD;
Ciprofloxacin: Antibiotic therapy for complicated UTI&#xD;
Amoxicillin-clavulanate: Antibiotic therapy for complicated UTI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiologic Success</title>
          <description>Microbiologic success is defined as demonstrating &lt;1000 CFU/mL of the baseline urpathogen by quantitative urine culture</description>
          <population>Analysis population is the microbiologic modified intent-to-treat population (all modified intent-to-treat patients with a positive study entry urine culture within 48 hours prior to first dose, defined as &gt;100,000 CFU/mL of a uropathogen and no more than 2 species of a uropathogen &gt;100,000 CFU/mL; if 1 of the uropathogens was also isolated from baseline blood culture, however, the patient was included in this population regardless of the baseline urine culture result).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="444"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316"/>
                    <measurement group_id="O2" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of informed consent through the final visit, an average of 28 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sulopenem</title>
          <description>Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Sulopenem: Antibiotic therapy for complicated UTI&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic therapy for complicated UTI</description>
        </group>
        <group group_id="E2">
          <title>Ertapenem</title>
          <description>Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment&#xD;
Ertapenem: Antibiotic therapy for complicated UTI&#xD;
Ciprofloxacin: Antibiotic therapy for complicated UTI&#xD;
Amoxicillin-clavulanate: Antibiotic therapy for complicated UTI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="697"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="697"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="698"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="697"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="697"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="697"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="697"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="697"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="697"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="697"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="697"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="697"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="697"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="697"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="697"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="697"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="697"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="697"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="697"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="697"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="698"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs will provide Iterum opportunity to review proposed publication/other type of disclosure before it's submitted/otherwise disclosed. PI will provide manuscripts, abstracts, or full text of intended disclosure (poster, invited speaker presentation, etc) to Iterum at least 30 days before submitted for publication/otherwise disclosed. If any patent action is required to protect intellectual property rights, PI agrees to delay disclosure for a period not to exceed an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical Development</name_or_title>
      <organization>Iterum Therapeutics</organization>
      <phone>18606614035</phone>
      <email>saronin@iterumtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

